Paclitaxel is a chemotherapy drug commonly used to treat breast and ovarian cancer, but some tumours can become resistant over time and start growing again.

Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.

Once ovarian cancer becomes resistant to multiple types of chemotherapy, fewer treatment options exist and the focus becomes lengthening patients' survival periods.